Education
About Us
Working with TipRanks
Follow Us
Senseonics Holdings Inc (SENS)
:SENS
SENS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $1.40
Previous CloseN/A
Volume3.00M
Average Volume (3M)4.38M
Market Cap
$494.06M
Enterprise Value$335.41M
Total Cash (Recent Filing)$74.60M
Total Debt (Recent Filing)$60.63M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 13, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding654,216,060
10 Day Avg. Volume2,913,424
30 Day Avg. Volume4,382,133
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.49
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit108.51
Enterprise Value/Ebitda-4.80
Forecast
1Y Price Target
$1.70Price Target Upside123.68% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Senseonics Holdings News
PremiumCompany Announcements
Senseonics Earnings Call: Eversense 365 Shines Amid Challenges
PremiumCompany Announcements
Senseonics Reports Growth and Eversense 365 Launch
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionPhysicians expect the US continuous glucose monitoring category to expand over 20%, surpassing the growth forecasts of market leaders.
Patient Base GrowthThe approval of the Eversense 365 system resulted in a 56% increase in the patient base, highlighting strong growth potential.
Product DifferentiationThe Eversense 365 platform is the only FDA-approved implantable CGM cleared for continuous blood glucose monitoring for 12 months, offering a significant advantage over competing platforms worn externally for just 10-14 days.
Bears Say
CompetitionThere is skepticism about SENS's ability to gain traction in the CGM market against established competitors, despite the 365-day indication.
Financial PerformanceSenseonics reported a net loss of $15.5M in 4Q24, although better than forecasted, indicating ongoing financial challenges.
Stock ValuationSENS shares are seen as expensive, trading at a high multiple of projected sales, with ongoing cash burn increasing dilution risk.
---
Ownership Overview
4.80% Insiders
4.18% Mutual Funds
0.02% Other Institutional Investors
85.60% Public Companies and
Individual Investors
SENS FAQ
What was Senseonics Holdings Inc’s price range in the past 12 months?
Senseonics Holdings Inc lowest stock price was $0.25 and its highest was $1.40 in the past 12 months.
What is Senseonics Holdings Inc’s market cap?
Senseonics Holdings Inc’s market cap is $494.06M.
When is Senseonics Holdings Inc’s upcoming earnings report date?
Senseonics Holdings Inc’s upcoming earnings report date is May 13, 2025 which is in 15 days.
How were Senseonics Holdings Inc’s earnings last quarter?
Senseonics Holdings Inc released its earnings results on Mar 03, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.012.
Is Senseonics Holdings Inc overvalued?
According to Wall Street analysts Senseonics Holdings Inc’s price is currently Undervalued.
Does Senseonics Holdings Inc pay dividends?
Senseonics Holdings Inc does not currently pay dividends.
What is Senseonics Holdings Inc’s EPS estimate?
Senseonics Holdings Inc’s EPS estimate is -0.02.
How many shares outstanding does Senseonics Holdings Inc have?
Senseonics Holdings Inc has 654,216,060 shares outstanding.
What happened to Senseonics Holdings Inc’s price movement after its last earnings report?
Senseonics Holdings Inc reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -19.54%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc?
Currently, no hedge funds are holding shares in SENS
---
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.70 (123.68% Upside)
$1.70 (123.68% Upside)
Blogger Sentiment
Bullish
SENS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $135.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.62%
12-Months-Change
Fundamentals
Return on Equity
-166.29%
Trailing 12-Months
Asset Growth
-27.33%
Trailing 12-Months
Company Description
Senseonics Holdings Inc
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
---
SENS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call for Senseonics highlighted significant progress with the launch of the Eversense 365, resulting in increased patient adoption and prescriber growth. However, financial challenges remain, including flat revenue growth and increased net losses, with particular difficulties in the European market. Despite these challenges, the company's advancements in technology and strong partnerships indicate potential for future growth.Read More>---
SENS Stock 12 Month Forecast
Average Price Target
$1.70
▲(123.68% Upside)
Technical Analysis
---